[Weight change, cardiometabolic risk and the impact of antidiabetic medications in type 2 diabetic patients].
In the first part of this review article, the prognostic impact of weight and weight changes in terms of clinical outcomes and metabolic control is reviewed, through the analysis of the results of several large cohorts and prospective studies of diabetic patients followed in "real world" settings. The second part of the review focuses on the impact of antidiabetic medications on weight, emphasising the importance of a comprehensive approach, taking into account weight, in the management of diabetic patients.
Danchin
N
N
Division maladies coronaires et soins intensifs, faculté Paris Descartes, hôpital européen Georges-Pompidou, AP-HP, 20, rue Leblanc, 75015 Paris, France. nicolas.danchin@egp.aphp.fr
Eschwège
E
E
Bekka
S
S
Krempf
M
M
D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D019317:Evidence-Based Medicine; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D024821:Metabolic Syndrome / Q000517:prevention & control*; D009765:Obesity / Q000517:prevention & control*; D011379:Prognosis; D011787:Quality of Health Care; D012306:Risk
D007004:Hypoglycemic Agents